Pathstone Holdings
RARE icon

Pathstone Holdings’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pathstone Holdings’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.52M Buy
45,392
+8,372
+23% +$208K ﹤0.01% 1284
2026
Q1 		$776K Buy
37,020
+2,681
+8% +$60.4K ﹤0.01% 1539
2025
Q4 		$790K Buy
34,339
+413
+1% +$13.6K ﹤0.01% 1540
2025
Q3 		$1.02M Buy
+33,926
New +$1.02M ﹤0.01% 1416
2025
Q1 		– Sell
-10,363
Closed -$436K – 2360
2024
Q4 		$436K Sell
10,363
-552
-5% -$27.4K ﹤0.01% 1786
2024
Q3 		$606K Buy
10,915
+1,749
+19% +$89.1K ﹤0.01% 1635
2024
Q2 		$377K Buy
9,166
+3,998
+77% +$171K ﹤0.01% 1838
2024
Q1 		$241K Buy
+5,168
New +$244K ﹤0.01% 2047

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Pathstone Holdings's RARE Position: Q2 2026 in Review

Pathstone Holdings increased its Ultragenyx Pharmaceutical (RARE) stake by 23% in Q2 2026, buying an estimated $208K and bringing the position to 45,392 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #1284.

Pathstone Holdings first reported a position in RARE in Q1 2024 and has held it in 8 quarters since. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Pathstone Holdings held 45,392 shares of Ultragenyx Pharmaceutical worth $1.52M as of Q2 2026.
  • Pathstone Holdings bought 8,372 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $208K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1284 holding.
  • Pathstone Holdings first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and has held it in 8 quarters since.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.